REG - Eden Research plc - Change of Nominated Adviser and Broker

Eden ResearchAnnouncement

01/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231101:nRSA9289Ra&default-theme=true

RNS Number : 9289R  Eden Research plc  01 November 2023

1 November 2023

 

 

Eden Research

("Eden" or "the Company")

 

Change of Nominated Adviser and Broker

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable
biopesticides and plastic-free formulation technology for use in the global
crop protection, animal health and consumer products industries, announces
that, following the completion of the all share merger between Cavendish
Securities plc (previously named Cenkos Securities plc) and Cavendish
Financial plc (previously named finnCap Group plc), as a consequence of
internal reorganisation within the Cavendish Group, the Company has changed
its Nominated Adviser and Broker from Cavendish Securities plc to Cavendish
Capital Markets Limited

 

 

For further information contact:

 

 Eden Research plc                                                 www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                                        01285 359 555

Alex Abrey

 Cavendish Capital Markets Limited (Nominated advisor and broker)
 Giles Balleny / George Lawson (corporate finance)                 020 7220 0500

Michael Johnson (sales)

 Hawthorn Advisors (Financial PR)
 Simon Woods                                                       eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 Felix Meston

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has two products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide
which initially targets a key disease affecting grapes and other high-value
fruit and vegetable crops.  It is a useful tool in crop defence programmes
and is aligned with the requirements of integrated pest management programmes.
It is approved for sale in a number of key countries whilst Eden and its
partners pursue regulatory clearance in new territories thereby growing Eden's
addressable market globally.

 

Cedroz™ is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal
efficacy of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to enhance their
performance and ease-of-use. Sustaine microcapsules are naturally-derived,
plastic-free, biodegradable micro-spheres derived from yeast. It is one of the
only viable, proven and immediately registerable solutions to the
microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol
EDEN. It was awarded the London Stock Exchange Green Economy Mark in January
2021, which recognises London-listed companies that derive over 50% of their
total annual revenue from products and services that contribute to the global
green economy. Eden derives 100% of its total annual revenues from sustainable
products and services.

 

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPDFLFXXBLLFBX